Capricor Therapeutics (CAPR) Operating Margin (2016 - 2025)
Historic Operating Margin for Capricor Therapeutics (CAPR) over the last 16 years, with Q4 2024 value amounting to 26.67%.
- Capricor Therapeutics' Operating Margin fell 160700.0% to 26.67% in Q4 2024 from the same period last year, while for Sep 2025 it was 258.87%, marking a year-over-year decrease of 1312400.0%. This contributed to the annual value of 106.41% for FY2024, which is 107800.0% down from last year.
- Per Capricor Therapeutics' latest filing, its Operating Margin stood at 26.67% for Q4 2024, which was down 160700.0% from 575.24% recorded in Q3 2024.
- Over the past 5 years, Capricor Therapeutics' Operating Margin peaked at 10.6% during Q4 2023, and registered a low of 23211.04% during Q3 2020.
- In the last 5 years, Capricor Therapeutics' Operating Margin had a median value of 491.12% in 2022 and averaged 3533.9%.
- In the last 5 years, Capricor Therapeutics' Operating Margin crashed by -220653700bps in 2020 and then skyrocketed by 45039700bps in 2021.
- Quarter analysis of 5 years shows Capricor Therapeutics' Operating Margin stood at 7229.02% in 2020, then soared by 66bps to 2490.75% in 2021, then soared by 66bps to 840.33% in 2022, then skyrocketed by 99bps to 10.6% in 2023, then plummeted by -152bps to 26.67% in 2024.
- Its Operating Margin stands at 26.67% for Q4 2024, versus 575.24% for Q3 2024 and 291.86% for Q2 2024.